Abstract 1341P
Background
The aim of PISCES study is to assess the molecular testing, treatment patterns and clinical outcomes among Chinese patients progressed on first-line (1L) EGFR-TKI monotherapy in real-world setting.
Methods
This prospective study enrolled EGFR mutant, locally advanced or metastatic NSCLC patients progressed on 1L EGFR-TKI monotherapy from May 2020 to May 2021 in 16 Chinese hospitals. The treatment patterns and clinical outcomes were recorded.
Results
292 patients received 1L EGFR-TKI monotherapy were enrolled. 93.8% (274/292) of patients received first/second generation (1/2G) EGFR-TKI and 6.2% (18/292) received third generation (3G) EGFR-TKI. 74.8% (205/274) of patients who progressed on 1L 1/2G EGFR-TKI underwent genetic testing, and 47.8% (98/205) of them were T790M positive (T790M+). 91.8% (90/98) of T790M+ patients received 3G EGFR-TKI as 2L therapy. Among the 107 patients with T790M negative (T790M-), 47.8% (51/107) received 3G EGFR-TKI, 25.2% (27/107) received chemotherapy and 8.4% (9/107) received prior 1/2G EGFR-TKI plus local therapy as 2L therapy. Among 18 patients progressed on 1L 3G EGFR-TKI, half (9/18) of them received chemotherapy, 27.8% (5/18) switched to another 3G EGFR-TKI. The overall median PFS (mPFS) of patients who had received 2L treatment was 9.1 months (95%CI, 7.6-11.2). The mPFS of patients receiving 2L 3G EGFR-TKI, prior 1/2G EGFR-TKI plus local therapy, and chemotherapy was 10.5 months (95%CI, 8.7-13.7), 10.2 months (95%CI, 5.3-19.2) and 5.5 months (95%CI, 3.3-8.6), respectively. Among those receiving 2L 3G EGFR-TKI treatment, T790M+ patients achieved significantly longer mPFS compared to T790M- patients (13.7 vs 7.6 months, P=0.012). For patients with T790M-, the mPFS was comparable (7.6 vs 5.5 months, P=0.07) when received 3G EGFR-TKI and chemotherapy as 2L therapy.
Conclusions
Most patients progressed on 1L EGFR-TKI monotherapy underwent genetic testing in Chinese real-world setting. The vast majority of T790M+ patients received 3G EGFR-TKIs treatment. Although almost half of T790M- patients received 3G EGFR-TKI as 2L therapy, these patients achieved suboptimal clinical outcome.
Clinical trial identification
NCT04207775.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1363P - Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK+ Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
Presenter: Emanuele Vita
Session: Poster session 19
1364P - ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 19
1365P - Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Jonathan Priantti
Session: Poster session 19
1366P - Association between the adverse events and serum concentrations of lorlatinib in patients with advanced ALK-positive lung cancer
Presenter: Yukiko Shimoda
Session: Poster session 19
1367P - Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453
Presenter: Barend Sikkema
Session: Poster session 19